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Abstract
Enzyme-catalyzed, post-translational modifications of core histones have been implicated in the complex changes in gene
expression that drive early mammalian development. However, until recently the small number of cells available from the
preimplantation embryo itself has prevented quantitative analysis of histone modifications at key regulator genes. The
possible involvement of histone modifications in the embryo’s response to extracellular signals, or as determinants of cell
fate or lineage progression, remains unclear. Here we describe the use of a recently-developed chromatin
immunoprecipitation technique (CChIP) to assay histone modification levels at key regulator genes (Pou5f1, Nanog, Cdx2,
Hoxb1, Hoxb9) as mouse embryos progress from 8-cell to blastocyst in culture. Only by the blastocyst stage, when the
embryonic (Inner Cell Mass) and extra-embryonic (Trophoblast) lineages are compared, do we see the expected association
between histone modifications previously linked to active and silent chromatin, and transcriptional state. To explore
responses to an environmental signal, we exposed embryos to the histone deacetylase inhibitor, anti-epileptic and known
teratogen valproic acid (VPA), during progression from 8-cell to morula stage. Such treatment increased H4 acetylation and
H3 lysine 4 methylation at the promoters of Hoxb1 and Hoxb9, but not the promoters of Pou5f1, Nanog,Cdx2 or the
housekeeping gene Gapdh. Despite the absence of detectable Hoxb transcription, these VPA-induced changes were
heritable, following removal of the inhibitor, at least until the blastocyst stage. The selective hyperacetylation of Hoxb
promoters in response to a histone deacetylase inhibitor, suggests that Hox genes have a higher turnover of histone
acetates than other genes in the preimplantation embryo. To explain the heritability, through mitosis, of VPA-induced
changes in histone modification at Hoxb promoters, we describe how an epigenetic feed-forward loop, based on cross-talk
between H3 acetylation and H3K4 methylation, might generate a persistently increased steady-state level of histone
acetylation in response to a transient signal.
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Introduction
Specific post-translational modifications of core histones are a
central component in the complex network of epigenetic
mechanisms by which genes are activated and silenced [1].
Modifications are put in place and maintained by the balanced
activity of families of modifying and demodifying enzymes, the
activities of which are influenced by the actions of metabolites and
a variety of environmental chemicals [2]. These enzymes, and the
modifications they put in place, provide a potential interface
through which the environment interacts with the genome [3]. It
has also been suggested that specific combinations of histone
modifications may constitute a code that determines the
transcriptional state of chromatin [4,5,6]. The code operates, in
part, by providing, on the nucleosome surface, an array of
modifications that are recognised, individually or in combination,
by non-histone proteins that, in turn, exert functional effects. The
existence of such interactions and their involvement in ongoing
chromatin functions is no longer in doubt and proteins that bind
selectively with modified histones, often with chromatin modifying
activities, are being identified in growing numbers [7]. However,
despite this it remains uncertain whether histone modifications can
operate as a true code, able to determine and predict future
transcriptional states [8,9]. A histone code could play a key role in
regulating patterns of gene expression through development, but
two conditions must be met for this to occur. First, specific histone
modifications must be predictive of transcription, even if not
directly causative, rather than just reflecting transcriptional states
determined by other epigenetic factors. Second, histone modifi-
cations induced by developmental or environmental cues and with
potential coding roles, must be heritable from one cell generation
to the next, in the absence of induced transcriptional change. Both
these conditions remain to be demonstrated.
Changes in histone modification seem to be closely involved in
the complex changes in gene expression that drive early
development [10]. Turnover of acetate groups on bulk histones
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stage [11] and microscopical approaches have revealed fascinating
inter-blastomere variation in global histone modification levels
during the cleavage stages [12,13]. However, the great majority of
bulk histones analysed by western blotting or microscopy, are
derived from intergenic chromatin and the patterns of modifica-
tion observed will not necessarily reflect those present across
individual genes. If we are to understand the mechanisms that
underpin developmental decisions made during early embryogen-
esis, it is essential to explore the detailed epigenetic properties of
individual genes in the early embryo itself, where cells are present
in their normal developmental niche. Until recently, such analysis
has not been possible, largely because the small number of cells
obtainable has precluded the use of Chromatin ImmunoPrecip-
itation (ChIP), the only experimental approach capable of
providing such information. To address this, we recently
developed a variant of ChIP (CChIP) that uses ‘‘carrier’’
chromatin from Drosophila cells to allow immunoprecipitation of
chromatin from as few as 100 mammalian cells [14]. We showed
that this approach can quantify histone modifications across key
regulator genes such as Nanog and Cdx2 in the mouse blastocyst
[14].
Here we use CChIP to define patterns of histone modification at
key genes as mouse embryos progress from the 2-cell to blastocyst
stage and to show how this pattern can be changed by an
environmental agent, namely the deacetylase inhibitor and
teratogen valproic acid (VPA) [15,16,17]. We find that VPA
treatment at the 8-cell to morula stage exerts gene-specific effects,
with increased histone acetylation and H3K4 methylation at the
transcriptionally silent Hoxb1 and Hoxb9 promoters, but little or no
effect at the promoters of other genes, both active and silent.
Crucially, the VPA-induced changes in histone modification are
transmitted, in the absence of inhibitor or of detectable
transcription, through to the blastocyst stage, thereby meeting
one of the conditions necessary for a predictive histone code.
Results
Valproate slows development and selectively alters gene
expression
Valproic acid (VPA, usually used as the sodium salt), like other
short chain fatty acids, is a broad spectrum inhibitor of both class I
and class II histone deacetylases (HDACs) and causes rapid
hyperacetylation of bulk histones when applied to cultured cell
lines [17]. In common with other HDAC inhibitors, it also leads to
increased mono-, di- and tri-methylation of H3 lysine 4, but not of
other methylatable histone lysines [18,19]. This global change may
reflect the preferential methylation of hyperacetylated H3 by SET-
domain methyltransferases, demonstrated by in-vitro assays [18],
or the physical and functional association of histone deacetylases
and the demethylase KDM1/LSD1 [20]. Although the effects of
VPA on bulk histone modifications are well defined, the extent to
which they are reflected in altered histone modifications at control
regions of defined genes, has not so far been reported.
The experimental design used to monitor changes in histone
modification in the developing pre-implantation embryo in the
presence and absence of VPA, is shown in Figure 1A. Mouse 2-cell
embryos were grown in culture for 24 h, at which stage 8-cell
embryos were separated into groups of about 50 and further
cultured for 18 h (ie. at least one complete cell cycle) in medium
with or without 1 mM VPA. In cultured cell lines, VPA slows cell
cycle progression and increases apoptosis [17]. In treated embryos,
progression to the blastocyst stage was slowed, but we detected no
increase in gross morphological defects (Fig. 1A and data not
shown). After 18 h the great majority of embryos in the treated
group developed to the morula stage, while embryos in the
untreated groups had reached the morula or early cavitating
blastocyst stage (Table 1, Fig. 1A). Some treated and untreated
embryos were immediately harvested for CChIP, while others
were washed several times and cultured for an additional 24 h in
medium without VPA. At this stage nearly all untreated embryos
had reached the mid- to late- (expanded) blastocyst stage while
progression of the VPA- treated embryos was relatively retarded,
with a higher frequency of cavitating and early blastocysts (Table 1,
Fig. 1A). Immunofluorescence labelling with antibodies to
acetylated H4 showed essentially uniform staining of nuclei in
the 8-cell, morula and blastocyst, with no detectable distortion of
either nuclear morphology or the largely uniform intranuclear
distribution of acetylated histone (Fig. 1B).
Evenwithpooledembryos,thenumberofcellsavailableinevitably
restrictsthenumberofhistonemodificationsandthenumberofgenes
that can be tested by CChIP [14]. We chose to assay three
modifications, namely H4 acetylated at lysine 8 (H4K8ac) and H3
tri-methylated at lysine 4 (H3K4me3), modifications associated with
transcriptionally active promoters, and H3 di-methylated at lysine 9
(H3K9me2), generally associated with transcriptionally silent pro-
moters[1].Wefirsttestedthreekeyregulatorgenes,thepluripotency
genesPou5f1andNanog,a ndCdx2,ageneessentialfortrophectoderm
formation[21,22,23].Thethreegenesshowverydifferentexpression
patterns.Microscopicalanalysisoftheproteinproducts[24]indicates
thatPou5f1isexpressedstronglyanduniformlyinallcellsatthe8-cell
stage and beyond, while Nanog and Cdx2 are expressed relatively
weakly(Nanog) or not at all (Cdx2) at the 8-cellstage and insomecells,
but not others, in the morula. We used RTQ-PCR to confirm
expression of Pou5f1 and Nanog at the 8-cell to morula stage and to
show that expression was moderately enhanced in VPA-treated
morula-stage embryos (Fig. 1C). Enhanced expression was lost
following growth to the blastocyst stage in the absence of inhibitor,
though by this stage overall expression had fallen several-fold,
presumablyduetosilencingof these twogenesinthe trophectoderm,
the most numerous cell population in the blastocyst (Fig. 1C). In
contrast, Cdx2 expression was modestly reduced by VPA treatment,
but rose gradually as development progressed (Fig. 1C).
Histone modifications at key regulator genes do not
reflect transcriptional status prior to the blastocyst stage
Levels of H4K8ac, H3K4me3 (often associated with active
chromatin) and H3K9me2 (often associated with silent chromatin)
at the promoters of Pou5f1, Nanog, Cdx2 and Gapdh were assayed by
CChIP in 8-cell and morula stage embryos. All three modifications
show little correlation with transcriptional status (ranging from
constitutively active Gapdh to silent Cdx2) and only modest
developmental changes from 8-cell to morula (Fig. 2, compare
8-cell – and Morula -, supplementary Tables S1, S2). Similar
results were obtained with antibodies to H4 acetylated at lysine 16
(H4K16ac), again with no correspondence between acetylation
and transcriptional state (supplementary Fig. S1). Levels of both
H4K16ac and H4K8ac were lower at the promoter of the
constitutively active housekeeping gene Gapdh than at the
promoters of the three lineage specific genes tested (Fig. 2,
supplementary Fig. S1).
Because of the lineage-dependent expression patterns of Pou5f1,
Nanog and Cdx2 [23,24], we fractionated blastocysts into ICM and
trophectoderm. In the ICM, where they are transcriptionally
active, the Pou5f1 and Nanog promoters are relatively rich in
H4K8ac and H3K4me3, and depleted in H3K9me2, while in the
trophectoderm, where they are silent, they are relatively rich in
H3K9me2 and depleted in H4K8ac and H3K4me3 (Fig. 2,
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PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e6086Figure 1. Effects of valproic acid (VPA) on developmental progression, morphology and expression of key regulator genes in
cultured mouse embryos. A. Cryopreserved 2-cell Balb/c mouse embryos were thawed and cultured with or without 1 mM sodium valproate
(VPA) as shown. Pooled embryos were harvested for CChIP at the times indicated. Photographs show representative examples of embryos at the
stages indicated. EM= early morula, LM=late morula, EC=early cavitating blastocyst, EB=early blastocyst, MB=mid-expanded blastocyst, LB=late-
expanded blastocyst. Bar=40 mm. B. Intranuclear distribution of acetylated histone H4 in 8-cell, morula and blastocyst stage embryos treated or
untreated with 1 mM VPA at the 8-cell to morula stage. C. Effect of VPA treatment on expression of Cdx2, Nanog and Pou5f1, relative to ActB,i n
cultured embryos assayed by RTQ-PCR. Cryopreserved 2-cell embryos were grown to the morula (42 h), blastocyst (66 h) or hatching blastocyst (90 h)
either untreated (VPA -) or after growth for 18 h in 1 mM VPA from the 8-cell to morula stage (+ VPA). In this series of experiments, embryos were
grown for longer than usual (up to 90 h, see text). VPA treatment enhanced expression of Nanog and Pou5f1 at the morula stage (42 h), but this was
lost by the blastocyst stage, with a fall of several-fold in transcript levels in both treated and untreated embryos. Cdx2 expression was unaffected by
VPA and showed a slight progressive increase as embryos progressed from morula to hatching blastocyst.
doi:10.1371/journal.pone.0006086.g001
Table 1. Effect of valproic acid at the 8-cell to morula stage (24–42 h) on developmental progression of mouse embryos grown
from the 2-cell stage in culture.
Treatment, time in culture Stage
Total started Morula Cavitating Early blast. Mid/Late blast.
Untreated 42 h 140 116 (83%) 24 (17%) 0 0
+VPA 24–42 h 140 126 (90%) 0 0 0
Untreated 66 h 89 0 0 0 86 (97%)
+VPA 24–42 h; -VPA 42–66 h 78 0 15 (19%) 63 (81%) 0
Stages were determined by morphology, as illustrated in Fig. 1A.
doi:10.1371/journal.pone.0006086.t001
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previous results [14]. The Cdx2 promoter, active in the
trophectoderm and silent in the ICM, shows the opposite pattern
of modification, consistent with its transcriptional status (Fig. 2).
Thus, levels of histone modification typical of active and silent
genes are in place by the blastocyst stage of development, where
they reflect transcriptional status. In contrast, at earlier stages the
relationship between histone modifications and gene expression
levels is less clear cut.
VPA induces changes in histone modification at Hoxb
genes but not at other regulator or housekeeping genes
We detected no significant change in histone acetylation at the
promoters of Cdx2, Pou5f1, Nanog and Gapdh in embryos treated
with VPA from 8-cell to morula-stage (compare Morula – with
Morula + in Fig. 2). The only major VPA-induced change at these
four genes is an approximately three-fold increase in H3K4me3 at
the Nanog promoter, a fold-change that reflected primarily the low
level of this modification prior to VPA-treatment and that was lost
by the blastocyst stage (Fig. 2, supplementary Tables S1, S2). This
restricted response to VPA is surprising in view of the global
histone hyperacetylation detected in preimplantation embryos and
ES cells exposed to HDAC inhibitors [11]. It is however,
consistent with the limited transcriptional response to HDAC
inhibitors seen in a number of different cell types [25] and with our
own recent ChIP data showing that VPA treatment causes little
change in acetylation at most promoters tested in both adult and
embryonic cultured cells (Vibhor Gupta, Hannah Stower, BMT,
unpublished). It seems that global changes in histone modification
are not necessarily reflected by changes at individual genes.
Figure 2. Quantitation by CChIP of levels of histone modification (Bound/Unbound ratio) at selected regions of the Pou5f1, Nanog,
Cdx2 and Gapdh promoters. CChIP was carried out as previously described with antibodies to the modifications indicated [14]. Specific
sequences were assayed in the precipitated (antibody Bound) and non-precipitated (Unbound) fractions by radioactive PCR [14]. Each column
represents the mean from at least two separate experiments calculated, in each experiment, from separate PCR reactions (in duplicate) run for 38 and
41 cycles. Error bars show SE. 8-cell embryos were all untreated (- , dark columns) before CChIP. Morula stage embryos were untreated (-, dark
columns) or had been treated with 1 mM VPA for 18 h from the 8-cell stage (+, pale columns). Blastocysts were derived from untreated morulae (-,
dark columns) or from morulae grown from the 8-cell stage in 1 mM VPA and then for a further 24 h without VPA (+, pale columns). Inner Cell Mass
(ICM) and trophectoderm (TE) were separated as described previously [14].
doi:10.1371/journal.pone.0006086.g002
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gene expression in mouse embryos, ES cells [26] and human
embryonal carcinoma cells [27] and can increase levels of H3
acetylation at Hoxb1 control elements in mouse ES cells [28]. It has
been suggested that aberrant Hox gene expression might account
for some of the teratogenic effects of VPA [27]. As shown in Fig. 3,
CChIP revealed a 1.5–5 fold increase in H4K8 acetylation and
H3K4 tri-methylation at the Hoxb1 and Hoxb9 promoters and the
Hoxb9 coding region in morula-stage embryos treated with VPA.
The increase was consistent across all three Hoxb regions tested
(supplementary Table S2) and the difference in modification levels
between the VPA-treated and untreated Hox genes was highly
significant (H4K8ac, P=0.006, H3K4me3, P=0.0008; this and
all subsequent comparisons use Student’s two-tailed paired t test).
In contrast, levels of the silencing mark H3K9me2 were
consistently lower in VPA-treated morulae (Fig. 3, supplementary
Table S2), though at a lower level of significance (P=0.016). To
ask whether the valproate-induced changes were contingent upon
progression from 8-cell to morula, we treated a group of 8-cell
embryos for just 2 h with 1 mM VPA. Both Hoxb1 and Hoxb9
showed increased levels of H4K8 acetylation after this brief
treatment, whereas Gapdh did not (Fig. 3, supplementary Table
S1). It seems that histone acetates are turning over rapidly at Hoxb
promoters in the 8-cell embryo, despite their transcriptional
quiescence.
VPA-induced changes in histone modification at Hoxb
genes are heritable through mitosis by a transcription-
independent mechanism
The increased levels of H4 acetylation and H3K4 tri-
methylation at Hoxb1 and Hoxb9 in VPA-treated morulae were
still present in the blastocysts derived from them after 24 h growth
in the absence of VPA (Fig. 3, compare Morula + and Blastocyst
+). At each of the three Hoxb regions tested, for both H4K8ac and
Figure 3. Effects of valproic acid (VPA) on levels of histone modification at Hoxb1, Hoxb9 and Gapdh in the mouse preimplantation
embryo. Levels of histone modification (Bound/Unbound ratio) were assayed by CChIP at selected regions of the Hoxb1 and Hoxb9 promoters, the
Hoxb9 coding region and the Gapdh promoter. 8-cell embryos were untreated (-, dark columns) or treated for 2 h with 1 mM VPA (+, pale columns)
before assay by CChIP for H4K8ac. Morula- and blastocyst-stage embryos were untreated (-, dark columns) or treated for 18 h with 1 mM VPA (+, pale
columns) as in Fig. 1A before CChIP.
doi:10.1371/journal.pone.0006086.g003
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was always higher in blastocysts derived from VPA-treated
morulae then from controls (Fig. 3 and supplementary Table
S4). The difference between blastocysts derived from VPA-treated
and control morulae in modification levels at Hoxb regions, was
significant (H4K8ac P=0.018, H3K4me3 P=0.00013). There is
an indication that the lower levels of H3K9me2 following VPA
treatment at the 8-cell to morula stage may also carry through to
the blastocyst (Fig. 3, supplementary Table S4), though the
statistical significance is borderline (P=0.04). The retention of
elevated levels of H4K8ac and H3K4me3 at Hox gene promoters
following removal of VPA contrasts with the behaviour of bulk
histones in cultured cell lines, where VPA-induced increases in
both modifications were lost within minutes of removal of the
inhibitor [18] (and unpublished results).
For the non-Hox genes tested in blastocysts, levels of H4K8ac,
H3K4me3 and H3K9me2 generally showed little change as a
result of VPA treatment at the 8-cell to morula stage (Fig. 2).
However, we note that levels of H4K8ac and H3K4me3 at
promoters of the pluripotency genes Nanog and Pou5f1, are
consistently lower in VPA-treated ICM (where they are active)
than in controls, while levels of H3K9me2 tend to be higher
(supplementary Table S3). Such changes are not seen in
trophectoderm, where these genes are silent, nor at promoters of
Gapdh or Cdx2 in either trophectoderm or ICM. These gene- and
lineage-specific epigenetic changes may result from the toxic
effects of VPA on growth or transcription rate.
Neither the VPA-induced changes in histone modifications at
Hox gene promoters, nor their heritability through mitosis, are
attributable to induced transcription. In both VPA-treated and
untreated embryos, transcription was undetectable for Hoxb9 and
barely detectable, even at high cycle numbers with radioactive
PCR, for Hoxb1 (Supplementary Fig. S2). In fact, we detected no
induced Hoxb expression in embryos transiently exposed to VPA,
even when grown to the hatching blastocyst stage, 90 h after
initiation of culture (results not shown).
Discussion
The ability of histone deacetylase inhibitor to induce a
mitotically heritable change in histone acetylation and gene
expression was first demonstrated in the yeast S.pombe [29].
Growth for several cell cycles in the presence of the HDAC
inhibitor Trichostatin A (TSA) induced hyperacetylation and
transcription in normally silent test genes inserted into centric
heterochromatin. The active, hyperacetylated state, though
reversible at low frequency, was retained through many cell cycles
in the absence of inhibitor. However, because acetylation and
transcription remained closely linked throughout these experi-
ments, it was not possible to determine which of these two factors
was the primary determinant of heritability [29]. More recently,
nuclear transplantation in Xenopus has been used to show that some
genes (eg. the endodermal gene edd) can retain a memory of an
active gene state, even in an inappropriate (eg. non-endodermal)
cell lineage [30]. The memory can be transmitted through up to
24 cell generations from zygote to tadpole. What makes this
particularly significant is that through the first 12 cleavage
divisions of the Xenopus embryo, there is no genomic transcription,
so the memory mechanism involved does not require active
transcription. Chromatin seems to have a role in this memory in
that the variant histone H3.3 and specifically its methylatable
lysine 4 residue, seems to be necessary for re-expression (memory)
of the active state after progression through the early cleavage
cycles [30]. H3.3 associates preferentially with active genes [31,32]
and may play a role in the maintenance of an active state, even in
the absence of ongoing transcription.
CChIP has allowed us, for the first time, to compare the
expression and chromatin modification patterns of selected genes
in the pre-implantation mouse embryo and to study the effects of
the histone deacetylase inhibitor and teratogen valproic acid
(VPA). There is, amongst the genes studied here, a surprising lack
of correlation between transcriptional activity and the levels of
histone modifications usually considered to be ‘‘activating’’,
namely H4 acetylation and H3K4 tri-methylation. Thus, VPA
increased acetylation levels at the silent Hoxb1 and Hoxb9
promoters without any detectable induction of transcription and
increased expression of Nanog and Pou5f1 without any parallel
increase in acetylation or H3K4 methylation. Similarly, in
untreated morula stage embryos, a comparison of active and
silent genes reveals no correlation between promoter levels of H4
acetylation and H3K4 tri-methylation and transcriptional status.
Only by the blastocyst stage, when genes that are active or silent in
the ICM and trophectoderm were compared, did the expected
relationships between ‘‘active’’ marks and transcriptional activity
become apparent. These findings may be due, at least in part, to
differences between cells in gene expression patterns, even in the
8-cell embryo. If, for example, only a minority of blastomeres were
to show enhanced Nanog expression in response to VPA, increased
transcript levels would be readily detected in pooled samples, but
increased promoter acetylation, even if it occurs in the minority of
expressing cells, would not be.
The increased level of H4 acetylation at Hoxb promoters in VPA
treated embryos shows that histone acetate groups are turning
over, despite the absence of detectable transcription. None of the
other genes tested, whether active (Nanog, Gapdh) or silent (Cdx2)
showed increased acetylation. This suggests a lack of turnover,
though it remains possible that turnover is mediated by
deacetylases resistant to inhibition by VPA, perhaps SirT1 or
other sirtuins [33]. The turnover of histone acetates at Hoxb
promoters provides a system through which the promoter
chromatin of selected genes can respond to environmental or
developmental signals that act on the relevant modifying and
demodifying enzymes. Perhaps, in the early embryo high turnover
of histone acetates marks genes that are silent but ‘‘poised’’, ready
to be expressed later in development [10]. This silent but poised
state contrasts with that of lineage determinants such as Pou5f1,
Nanog and Cdx2, where differing expression patterns are already
being put in place at the morula-blastocyst transition and earlier.
We show that VPA-induced increases in histone acetylation, and
contingent H3K4 methylation, at Hox gene promoters are not
sufficient to override silencing signals and induce transcription.
However, these VPA-induced changes are inherited, at least until
the blastocyst stage and in the continuing absence of detectable
transcription. This finding not only establishes that a change in
histone modification level induced by an environmental agent can
be heritable, but also provides a process by which the effects of a
transient, possibly stage-specific, signal might be transmitted to a
later developmental stage without initiating inappropriate tran-
scription [9].
In considering the mechanisms by which an induced increase in
acetylation could be maintained across cell generations, it is
important to remember that the measured level of acetylation
represents a dynamic equilibrium between the activities of
modifying and demodifying enzymes. Inhibition of deacetylases
will shift the equilibrium to a more acetylated level, but following
removal of the inhibitor, one would expect the steady state level at
gene promoters to return rapidly to its pre-inhibition levels, exactly
as seen in assays of bulk acetylation [18]. A possible mechanism is
Heritable Histone Modification
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acetylation and lysine 4 methylation on the H3 tail. In vitro assays
have shown that increased acetylation of the H3 tail domain
directly causes increased H3K4 methylation by generating a more
effective substrate for SET domain methyltransferases [18,20].
H3K4me3 is an important mark, selectively recognised by several
non-histone proteins, including CHD1, a component of the
SAGA- and SLIK-dependent histone acetyltransferase complexes
[34,35]. Thus, an inhibitor-induced increase in histone acetyla-
tion, with a consequent increase in H3K4 methylation, could
bring in additional acetyltransferases and thereby initiate an
increased steady-state level of histone acetylation that could be
maintained, even in the absence of inhibitor (Fig. 4). This cycle of
events constitutes a self-sustaining mechanism by which an
environmentally-induced increase in steady-state histone acetyla-
tion at selected genes could be maintained in a dynamic system.
If this model, or something like it, is correct, then the ability to
put in place a heritable epigenetic change in response to an
environmental agent, or to respond to that agent at all, will depend
on the presence of a group of enzymes of defined specificity (Fig. 4),
perhaps operating as a complex. Our recent studies in mouse ES
cells have shown that all Hoxb genes respond to VPA with
increased histone acetylation and H3K4 methylation, whereas
other genes do not (unpublished results). However, in contrast to the
situation in the embryo itself, these VPA-induced modifications
seem not to be heritable through mitosis (unpublished results).The
consistent differences between Hox genes and others, and between
different cell types and developmental stages, may reflect the
families of enzymes present at selected genomic regions, something
that is amenable to experimental testing.
Valproic acid (VPA) is a widely used preventive treatment for
seizures and bipolar disorder [36], but its use during pregnancy is
associated with an increased risk of congenital abnormalities, often
involving a characteristic mix of central nervous system and
craniofacial defects [16]. The persistence of VPA-induced Hox
gene hyperacetylation, raises the possibility that transient exposure
to VPA at the very earliest stages of pregnancy could result in
disorganised Hox gene expression at later stages, with consequent
morphological abnormalities [27]. However, it remains to be
shown whether altered histone modifications can drive altered
gene expression later in development. We find no evidence for
premature expression of Hoxb1 or Hoxb9 in VPA treated embryos
grown to the hatching blastocyst stage, suggesting that silencing
signals still predominate. It will be important to determine,
perhaps through re-implantation of VPA-treated embryos,
whether the induced changes in Hox gene acetylation reported
here can alter spatial or temporal patterns of Hox gene expression
later in development when silencing signals are being overridden.
Materials and Methods
Antibodies
Rabbit polyclonal antisera to H4K8ac, H4K16ac and
H3K4me3 were raised by immunization with synthetic peptides
conjugated to ovalbumin as previously described [37]. Antibodies
to H3K9me2 were from Upstate (now Millipore, Billerica, MA,
USA). Specificity was assayed by inhibition ELISA for all in-house
and commercial antisera and checked by western blotting. For all
antisera, cross-reaction with epitopes other than that against which
the antiserum was raised was insignificant.
Embryo culture and manipulation
Cryopreserved 2-cell Balb/c mouse embryos (Embryotech,
Haverhill, MA, USA) were thawed and cultured in M16 medium
(Specialty Media, now Millipore, Billerica, MA, USA) for differing
times up to the (expanded) blastocyst stage. Isolation of the inner
cell mass (ICM) was by immunosurgery [38], with minor
alterations [14]. Isolation of mural trophectodermal cells was
performed exactly as described previously [14].
Carrier Chromatin ImmunoPrecipitation, CChIP
For the CChIP procedure, Drosophila SL2 cells, cultured as
previously described [14] were pelleted and washed 3x in ice cold
PBS, 5 mM sodium butyrate. Cells were resuspended to
5610
7 cells/ml and 1 ml aliquots were mixed with a small
number (for these experiments, at least 100) of mouse cells derived
from pooled 8-cell, morula or blastocyst stage embryos. Chroma-
tin was prepared from the mixed sample and immunoprecipitated
Figure 4. An epigenetic feed-forward loop; a model that links
acetylation and lysine 4 methylation on the histone H3 tail and
that can maintain elevated levels of histone acetylation. (1)
Residues 1–14 of the N-terminal tail of histone H3 are shown
(boxed,single letter code), with lysines 4, 9 and 14 indicated. H3 lysines
9,14, 18 and 23 (only the first two are shown) can be acetylated (blue
disc) by various histone acetyltransferases (HATs) [2,41] and deacety-
lated by various deacetylases (HDACs) [2], mainitaining a dynamic
steady state level of acetylation. Vaproic acid (VPA) inhibits most
HDACs, thereby increasing acetylation levels. (2) H3 lysine 4 can be tri-
methylated (red discs) by SET-domain lysine methyltransferases,
specifically KMT2A-E, and demethylated by lysine demethylases,
specifically KDM5A-D. Elevated acetylation of the H3 tail increases the
H3K4 methylating activity of SET domain methyltransferases [18] (large
arrow), leading to enhanced K4 methylation of the acetylated tail
domain. (3) CHD1, a component of the SAGA/SLIK histone acetyltrans-
ferase complex, binds selectively to H3 tri-methylated at lysine 4 [34,35].
H3 acetylation is thus further enhanced (large arrow), both through
targeting of CHD1-linked acetyltransferase activities and because H3
methylated at lysine 4 is a better substrate for the SAGE/SLIK complex
[34,35]. Demethylation of K4 by KDM5A-D will return the cycle to step 2,
but while some acetylation is retained (at lysines 9, 14, 18 or 23), K4
methylation will be rapidly reinstated. The cycle will maintain elevated
levels of H3 acetylation, even after removal of the original inhibitor
(VPA). In the continuing presence of the necessary acetylating and
methylating enzymes, only complete deacetylation of the H3 tail will
break the cycle by returning it to step 1. Thus, even a transient exposure
to an inhibitor such as VPA could trigger a self-sustaining shift to a
higher steady-state level of acetylation and lysine 4 methylation.
doi:10.1371/journal.pone.0006086.g004
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detected in the immunoprecipitated (bound) and non-precipitated
(unbound) fractions by radioactive PCR with mouse-specific
primers. All PCR reactions were performed in duplicate with
mouse and Drosophila DNA controls run in parallel to monitor
cross-hybridization [14]. Aliquots were removed after 38 and 41
cycles, loaded onto 5% polyacrylamide gels and electrophoresed.
Gels were dried onto filter paper (SpeedGel System, Thermo
Fisher Scientific Inc., Waltham, MA, USA) for a minimum of
2 hours. Filters were exposed to a phosphor screen overnight and
scanned with a PhosphorImager (Typhoon 9200, Amersham,
UK). Examples are shown in supplementary Fig. S3. Intensity
values for each PCR product were analysed with Image Quant
software (Molecular Dynamics, Sunnyvale, CA, USA). Primer
pairs and Tm temperatures used are listed in Supplementary
Table S5
Expression analysis by RTQ-PCR
RNA was prepared from mouse embryos as previously described
[39]. Transcript levelsofPou5f1,Nanog,Cdx2 andActBwere quantified
by real time PCR using SYBR Green PCR master mix and an ABI
7900 Detection System (ABI Technologies Inc., Barnsley, UK). The
primer sequences are listed in Supplementary Table S6.
Immunofluorescence Labelling of Embryos
Immunofluorescence labelling of embryos was performed as
previously described [40] with modifications. Briefly, zona free
embryos were placed in a drop of ice-cold ethanol on Poly-Prep
slides (Sigma-Aldrich Co. Ltd, Poole, UK) under a dissecting
microscope. KCM buffer (120 mM KCl, 20 mM NaCl, 10 mM
Tris-HCl, pH 8, 0.5 mM EDTA, 0.1% Triton X-100) was added
for 10 minutes at room temperature. Excess KCM was removed
with PVA absorption spears (Altomed, Tyne and Wear, UK).
50 ml rabbit antibody in 1% BSA/KCM, was added and
incubated in a humid chamber at 4uC for 1 hour. Slides were
rinsed in KCM, followed by 50 ml of FITC-conjugated goat anti-
rabbit IgG antibody (Sigma) at650 dilution in 1% BSA/KCM.
After 1 hour as above, slides were rinsed, fixed in 4%
formaldehyde in KCM for 10 minutes and counterstained with
DAPI (1 mg/ml) in Vectorshield (Vector Labs, Burlingame, CA,
USA).
Supporting Information
Figure S1 CChIP analysis of H4K16 acetylation at selected
promoters in pooled 8-cell embryos or morulae.
Found at: doi:10.1371/journal.pone.0006086.s001 (0.05 MB
PDF)
Figure S2 Expression of Hoxb1 and Hoxb9 assayed by
radioactive PCR in embryos cultured with or without valproic
acid.
Found at: doi:10.1371/journal.pone.0006086.s002 (0.06 MB
PDF)
Figure S3 Examples of gels resolving 32P-labelled PCR
products generated from antibody bound and unbound fractions
derived by CChIP.
Found at: doi:10.1371/journal.pone.0006086.s003 (0.19 MB
PDF)
Table S1 ChIP data; 8-cell
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Table S2 ChIP data; morula
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Table S4 ChIP data; whole blastocyst
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Table S5 Primers used for CChIP analysis
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Table S6 Primers used for expression analysis
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